

Rev 2: February 2020  
FSN Ref: AN-FSN-008

FSCA Ref: AN-FSCA-008

Date: 2023-04-27

**Field Safety Notice**  
**Wip'Anios Excel**

**For Attention of:** Vigilance manager of the facility and the users of the affected products.

Dear customer,

We ask you to please review the information in this document and follow the appropriate actions outlined in section 3. Please return the reply form accompanying this FSN and return it to us as soon as possible.

Thank you for your cooperation and understanding.

Best regards,



ANIOS VIGILANCE

## **Field Safety Notice (FSN)**

<b>1. Information on Affected Devices</b>	
1.	1. Device Type(s) Ready to use wipes
1.	2. Commercial name(s) Wip'Anios Excel
1.	3. Primary clinical purpose of device(s) Disinfectant wipes for invasive medical devices
1.	4. Device Model/Catalogue/part number(s) Wip'Anios Excel <ul style="list-style-type: none"> <li>○ REF: 2446655Y6 (6 x 100 wipes)</li> <li>○ LOT: E16614S</li> </ul>

<b>2. Reason for Field Safety Corrective Action (FSCA)</b>	
2.	1. Description of the product problem In the framework of quality controls qualifications, we identified the presence of <i>Achromobacter</i> sp. in one of our products. As a precautionary measure we ask you to stop using the batches as specified in section 1.4 of this document until our investigations are finalized.
2.	2. Hazard giving rise to the FSCA <i>Achromobacter</i> sp. poses little medical risk to healthy people. However, it is a known cause of infections in hospitalized patients. Patients who have certain health problems like weakened immune systems, especially immunocompromised patients or in neonatal care, or chronic lung diseases, particularly those with cystic fibrosis, are at higher risk of infection.
2.	3. Probability of problem arising Taking into consideration the products' intended use, the probability of the bacteria infecting the at-risk patient population in case of use of a contaminated wipe is low.

3. Type of Action to mitigate the risk		
3.	<b>1. Action To Be Taken by the User</b>  <input checked="" type="checkbox"/> Identify Product <input checked="" type="checkbox"/> Quarantine Product <input type="checkbox"/> Return Device <input type="checkbox"/> Destroy Device  <input checked="" type="checkbox"/> If you are a distributor, notify your customers of this Field Safety Notice  <input type="checkbox"/> On-site device modification / inspection  <input type="checkbox"/> Follow patient management recommendations  <input type="checkbox"/> Take note of amendment / reinforcement of Instructions For Use (IFU)  <input type="checkbox"/> Other <input type="checkbox"/> None  <p>As a precautionary measure, we ask you to quarantine and to identify and physically isolate the products that you may have at your facility, while we complete our investigations.</p>	
3.	2. By when should the action be completed?	Immediately
3.	3. Is customer Reply Required? (If yes, form attached specifying deadline for return)	Yes
3.	<b>4. Action Being Taken by the Manufacturer</b>  <div style="display: flex; justify-content: space-between;"> <div> <input type="checkbox"/> Product Removal  <input type="checkbox"/> Software upgrade  <input checked="" type="checkbox"/> Other             </div> <div> <input type="checkbox"/> On-site device modification/inspection  <input type="checkbox"/> IFU or labelling change  <input type="checkbox"/> None             </div> </div> <p>Root-cause analysis including extensive testing and quarantining of potentially impacted products.</p>	

4. General Information		
4.	1. FSN Type	New
4.	2. Further advice or information already expected in follow-up FSN?	Yes
4.	3. If follow-up FSN expected, what is the further advice expected to relate to:	
	We will inform about possible use or destruction instruction.	
4.	4. Manufacturer information (For contact details of local representative refer to page 1 of this FSN)	
	a. Company Name	Laboratoires Anios
	b. Address	1 rue de l'Espoir, 59260 Lezennes, FRANCE
	c. Website address	www.anios.com
4.	5. The Competent (Regulatory) Authority of your country has been informed about this communication to customers.	
4.	6. List of attachments/appendices:	Annex I – FSN Reply Form
4.	7. Name/Signature	<div> <div>Nicky Sullivan, (VP Quality and MPD)</div> <div></div> </div> <div> <div>Christian Jost, (Principal Specialist Regulatory Affairs)</div> <div></div> </div>

Transmission of this Field Safety Notice	
	<p>This notice needs to be passed on all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred. (As appropriate)</p> <p>Please transfer this notice to other organisations on which this action has an impact. (As appropriate)</p> <p>Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action.</p> <p>Please report all device-related incidents to the manufacturer, distributor or local representative, and the national Competent Authority if appropriate, as this provides important feedback.</p>